102 related articles for article (PubMed ID: 4023710)
1. Antibody-directed urokinase: a specific fibrinolytic agent.
Bode C; Matsueda GR; Hui KY; Haber E
Science; 1985 Aug; 229(4715):765-7. PubMed ID: 4023710
[TBL] [Abstract][Full Text] [Related]
2. Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin.
Bode C; Runge MS; Newell JB; Matsueda GR; Haber E
J Biol Chem; 1987 Aug; 262(22):10819-23. PubMed ID: 3611093
[TBL] [Abstract][Full Text] [Related]
3. Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.
Runge MS; Bode C; Matsueda GR; Haber E
Biochemistry; 1988 Feb; 27(4):1153-7. PubMed ID: 3130094
[TBL] [Abstract][Full Text] [Related]
4. Thrombolysis by a fibrin-specific antibody Fab'-urokinase conjugate.
Bode C; Runge MS; Newell JB; Matsueda GR; Haber E
J Mol Cell Cardiol; 1987 Apr; 19(4):335-41. PubMed ID: 3612817
[TBL] [Abstract][Full Text] [Related]
5. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.
Hagemeyer CE; Tomic I; Weirich U; Graeber J; Nordt T; Runge MS; Bode C; Peter K
J Thromb Haemost; 2004 May; 2(5):797-803. PubMed ID: 15099287
[TBL] [Abstract][Full Text] [Related]
6. A bispecific antibody enhances the fibrinolytic potency of single-chain urokinase.
Charpie JR; Runge MS; Matsueda GR; Haber E
Biochemistry; 1990 Jul; 29(27):6374-8. PubMed ID: 1698452
[TBL] [Abstract][Full Text] [Related]
7. Bispecific monoclonal antibodies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).
Bos R; Nieuwenhuizen W
Ann N Y Acad Sci; 1992 Dec; 667():428-30. PubMed ID: 1309066
[No Abstract] [Full Text] [Related]
8. Hybrid molecules: insights into plasminogen activator function.
Runge MS; Bode C; Haber E; Quertermous T
Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
[TBL] [Abstract][Full Text] [Related]
9. Chemical coupling of a monoclonal antisurfactant protein-B antibody to human urokinase for targeting surfactant-incorporating alveolar fibrin.
Ruppert C; Schmidt R; Grimminger F; Suzuki Y; Seeger W; Lehr CM; Günther A
Bioconjug Chem; 2002; 13(4):804-11. PubMed ID: 12121136
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
[TBL] [Abstract][Full Text] [Related]
11. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.
Bode C; Runge MS; Branscomb EE; Newell JB; Matsueda GR; Haber E
J Biol Chem; 1989 Jan; 264(2):944-8. PubMed ID: 2492021
[TBL] [Abstract][Full Text] [Related]
12. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
[No Abstract] [Full Text] [Related]
13. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
Bode C; Eberle T; Runge M; Haber E; Kübler W
Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
[No Abstract] [Full Text] [Related]
14. Hybridization to an anti-activated platelet monoclonal antibody enhances fibrinolytic potency on urokinase.
Du L; Yu RR; Hua ZC; Zhu DX; Wu GX; Ruan CG
Sci China B; 1993 Dec; 36(12):1483-9. PubMed ID: 8129836
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
16. Two-step targeting of urokinase to plasma clot provides efficient fibrinolysis.
Sakharov DV; Sinitsyn VV; Kratasjuk GA; Popov NV; Domogatsky SP
Thromb Res; 1988 Mar; 49(5):481-8. PubMed ID: 3376054
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
Gurewich V; Pannell R
Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
[TBL] [Abstract][Full Text] [Related]
18. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
19. [Study on the in vitro and in vivo thrombolytic efficacy of bispecific antifibrin-antiurokinase monoclonal antibodies].
Yuan H; Lin H; Zhu X; Zhang Y; Zhang X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Oct; 20(5):357-60. PubMed ID: 11717992
[TBL] [Abstract][Full Text] [Related]
20. The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.
Cassels R; Fears R; Smith RA
Biochem J; 1987 Oct; 247(2):395-400. PubMed ID: 3122725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
